Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes

References

• Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6(7):538–546.
   PubMed Web of Science ®Google Scholar
• Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56(4):686–695.
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai GG, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 2003;41(7):1071–1077.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772.
   PubMed Web of Science ®Google Scholar
• Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–495.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319–335.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100(5):899–904.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease. Arterioscler Thromb Vasc Biol. 2011;31(8):1716–1725.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N,  Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease. Circ Res. 2016;118(4):547–563.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. A test in context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol. 2017;70(13):1637–1646. .
   PubMed Web of Science ®Google Scholar
• Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. 2013;10(11):648–661.
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364–373. .
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–1295.
   Web of Science ®Google Scholar
• Katsiki N, Kolovou G. Postprandial lipid profile in patients with type 2 diabetes. Curr Med Res Opin. 2014;30(1):121.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Miyoshi T, Yunoki K, et al. Postprandial hyperlipidemia as a potential residual risk factor. J Cardiol. 2016;67(4):335–339.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141(3):358–367.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14(7):401–411.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298–1309.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.
   PubMed Web of Science ®Google Scholar
• Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24(2):95–109.
   PubMed Web of Science ®Google Scholar
• Chan DC, Pang J, Romic G, et al. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep. 2013;15(3):309.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;41(2):255–323.
   Web of Science ®Google Scholar
• Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–666.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1046–e1081.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Cartier L-J, Collins C, Lagace M, et al. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin Biochem. 2018;52:61–66.
   PubMed Web of Science ®Google Scholar
• Joint British Societies’ Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Suppl 2):ii1–ii67.
   PubMedGoogle Scholar
• Eriksson M, Zethelius B, Eeg-Olofsson K, et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. Eur J Prev Cardiol. 2011;18(1):97–105.
   Google Scholar
• Taskinen M-R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733–749.
   PubMed Web of Science ®Google Scholar
• Hiukka A, Fruchart-Najib J, Leinonen E, et al. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia. 2005;48(6):1207–1215.
   PubMed Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis. 2014;233(2):608–615.
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Hazzard WR, Porte D Jr., et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest. 1973;52(7):1578–1585.
   PubMed Web of Science ®Google Scholar
• Cohn JS, Johnson EJ, Millar JS, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 1993;34(12):2033–2040.
   PubMed Web of Science ®Google Scholar
• Karpe F, Bell M, Björkegren J, et al. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol. 1995;15(2):199–207.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999–1008.
   PubMed Web of Science ®Google Scholar
• Su JW, Nzekwu MM, Cabezas MC, et al. Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk. Eur J Clin Invest. 2009;39(9):741–754.
   PubMed Web of Science ®Google Scholar
• Smith D, Watts GF, Dane-Stewart C, et al. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest. 1999;29(3):204–209.
   PubMed Web of Science ®Google Scholar
• Welty FK, Lichtenstein AH, Barrett PH, et al. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol. 1999;19(12):2966–2974.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Saito T, Tamura A, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223(1–2):53–71.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Taniguchi T, Taketoh H, et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 1999;22(1):152–156.
   PubMed Web of Science ®Google Scholar
• Miyauchi K, Kayahara N, Ishigami M, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007;53(12):2128–2135.
   PubMed Web of Science ®Google Scholar
• Teng K-T, Chang C-Y, Kanthimathi MS, et al. Effects of amount and type of dietary fats on postprandial lipemia and thrombogenic markers in individuals with metabolic syndrome. Atherosclerosis. 2015;242(1):281–287.
   PubMed Web of Science ®Google Scholar
• Monfort-Pires M, Delgado-Lista J, Gomez-Delgado F, et al. Impact of the content of fatty acids of oral fat tolerance tests on postprandial triglyceridemia: systematic review and meta-analysis. Nutrients. 2016;8(9):580.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9(3):258–270.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profiles: executive summary of a 2019 expert panel statement. Curr Vasc Pharmacol. 2019;17(5):538–540.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, main text. Curr Vasc Pharmacol. 2019;17(5):498–514.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Watts GF, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, narrative review. Curr Vasc Pharmacol. 2019;17(5):515–537.
   PubMed Web of Science ®Google Scholar
• Maraki M, Aggelopoulou N, Christodoulou N, et al. Validity of abbreviated oral fat tolerance tests for assessing postprandial lipemia. Clin Nutr. 2011;30(6):852–857.
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Kanellos PT, Siami E, et al. Assessment of the validity and reproducibility of a novel standardized test meal for the study of postprandial triacylglycerol concentrations. Lipids. 2017;52(8):675–686.
   PubMed Web of Science ®Google Scholar
• Gavra P, Melidonis A, Iraklianou S, et al. Alterations in plasma triglyceride concentrations following two oral meals with different fat content in patients with type 2 diabetes mellitus. Curr Vasc Pharmacol. 2018;16(4):385–392.
   PubMed Web of Science ®Google Scholar
• Orem A, Yaman SO, Altinkaynak B, et al. Relationship between postprandial lipemia and atherogenic factors in healthy subjects by considering gender differences. Clin Chim Acta. 2018;480:34–40.
   PubMed Web of Science ®Google Scholar
• Maraki MI, Sidossis LS. Physiology in Medicine: update on lifestyle determinants of postprandial triacylglycerolemia with emphasis on the Mediterranean lifestyle. Am J Physiol Endocrinol Metab. 2015;309(5):E440–E449.
   PubMed Web of Science ®Google Scholar
• Thomsen C, Storm H, Holst JJ, et al. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr. 2003;77(3):605–611.
   PubMed Web of Science ®Google Scholar
• Leon-Acuna A, Torres-Pena JD, Alcala-Diaz JF, et al. Lifestyle factors modulate postprandial hypertriglyceridemia: from the CORDIOPREV study. Atherosclerosis. 2019;290:118–124.
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Salpea KD, Anagnostopoulou KK, et al. Alcohol use, vascular disease, and lipid-lowering drugs. J Pharmacol Exp Ther. 2006;318(1):1–7.
   PubMed Web of Science ®Google Scholar
• Ginsberg H, Olefsky J, Farquhar JW, et al. Moderate ethanol ingestion and plasma triglyceride levels. A study in normal and hypertriglyceridemic persons. Ann Inter Med. 1974;80(2):143–149.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S98–S110.
   PubMed Web of Science ®Google Scholar
• Weintraub MS, Charach G, Grosskopf I. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis. 1998;141(Suppl 1):S71–S75.
   PubMedGoogle Scholar
• Eleftheriadou I, Grigoropoulou P, Katsilambros N, et al. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev. 2008;4(4):340–356.
   PubMedGoogle Scholar
• Hein GJ, Baker C, Hsieh J, et al. GLP-1 and GLP-2 as Yin and Yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes. 2013;62(2):373–381.
   Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. Gut peptides are novel regulators of intestinal lipoprotein secretion: experimental and pharmacological manipulation of lipoprotein metabolism. Diabetes. 2015;64(7):2310–2318.
   PubMed Web of Science ®Google Scholar
• Verges B, Duvillard L, Pais de Barros JP, et al. Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2018;38(9):2198–2206.
   PubMed Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes. 2014;63(7):2394–2401.
   PubMed Web of Science ®Google Scholar
• Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 2013;12(1):8.
   PubMedGoogle Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs. 2016;25(2):145–158.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;12(11):1267–1271.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Lam KS, Chow CC, Tan KC, et al. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Curr Med Res Opin. 2016;32(6):1097–1108.
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF. Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism. 2012;61(1):3–11.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S111–S134.
   PubMedGoogle Scholar
• Pang J, Chan DC, Barrett PH, et al. Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects. Curr Opin Lipidol. 2012;23(4):303–309.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72(25):3320–3331.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Iovine C, Lilli S, Gentile A, et al. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. Eur J Clin Invest. 2006;36(8):560–565.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Santos RD, Aguilar-Salinas C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019;18(1):71.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.
   PubMed Web of Science ®Google Scholar
• Ooi EM, Watts GF, Ng TW, et al. Effect of dietary fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients. 2015;7(6):4416–4425.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. .
   PubMed Web of Science ®Google Scholar
• FDA approves use of Vascepa (icosapent ethyl) to reduce risk of cardiovascular events in certain adult patient groups. 2019 Dec 13. cited 2020 Mar 1. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular- events -certain-adult-patient-groups
   Google Scholar
• Sahebkar A, Simental-Mendia LE, Mikhailidis DP, et al. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2018;50(7):565–575.
   PubMed Web of Science ®Google Scholar
• Jamilian M, Tabassi Z, Reiner Z, et al. The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2020;123(7):792–799.
   PubMed Web of Science ®Google Scholar
• Yunoki K, Nakamura K, Miyoshi T, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis. 2011;217(2):486–491.
   PubMed Web of Science ®Google Scholar
• Hiramitsu S, Miyagishima K, Ishii J, et al. The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol. 2012;60(5):395–400.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Nezu U, Inazumi K, et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb. 2012;19(12):1093–1101.
   PubMed Web of Science ®Google Scholar
• Sharifi F, Hojeghani N, Mazloomzadeh S, et al. The efficacy of ezetimibe added to ongoing fibrate-statin therapy on postprandial lipid profile in the patients with type 2 diabetes mellitus. J Diabetes Metab Disord. 2013;12(1):24.
   PubMedGoogle Scholar
• Westerink J, Deanfield JE, Imholz BP, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: the PANACEA study. Atherosclerosis. 2013;227(1):118–124.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2016; 2105;372(25):2387–2397.
   Google Scholar
• Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–1582.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Alirocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17(5):633–643.
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Hu M, Zhang Y, et al. Evoocumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17(11):1447–1461.
   PubMed Web of Science ®Google Scholar
• Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014;35(33):2249–2259.
   PubMed Web of Science ®Google Scholar
• Chan DC, Wong AT, Pang J, et al. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. Clin Sci (Lond). 2015;128(6):379–385.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022–1032.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019;124(3):386–404. .
   PubMed Web of Science ®Google Scholar
• Bempedoic Acid FDA approval. Drugs@FDA: FDA-approved drugs. 2020 Feb 21 cited 2020 Mar 1. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211616
   Google Scholar
• Crosby J, Peloso GM, Auer PL, et al. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41.
   PubMed Web of Science ®Google Scholar
• Stitziel NO, Stirrups KE, Masca NG, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–1144.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–1133.
   PubMed Web of Science ®Google Scholar
• Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220–2227.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–221.
   PubMed Web of Science ®Google Scholar
• Paik J, Duggan S. Volanesorsen: first global approval. Drugs. 2019;79(12):1349–1354.
   PubMed Web of Science ®Google Scholar
• Zhang J, Rocha NA, McCullough PA. Contribution of ApoCIII to diabetic dyslipidemia and treatment with volanesorsen. Rev Cardiovasc Med. 2018;19(1):13–19.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296–297.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Banerjee P, Hamon S, et al. inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470–486.
   PubMed Web of Science ®Google Scholar